Chrysin a promising anticancer agent: recent perspectives

被引:19
作者
Shahbaz, Muhammad [1 ]
Naeem, Hammad [1 ]
Imran, Muhammad [2 ]
Ul Hassan, Hammad [1 ]
Alsagaby, Suliman A. [3 ]
Al Abdulmonem, Waleed [4 ]
Waqar, Ahmed Bilal [5 ]
Ghorab, Ahmed H. [6 ]
Abdelgawad, Mohamed A. [7 ]
Ghoneim, Mohammed M. [8 ,9 ]
Hussain, Muzzamal [10 ]
Al Jbawi, Entessar [11 ]
Ihsan, Amna [12 ]
机构
[1] Muhammad Nawaz Shareef Univ Agr Multan, Dept Food Sci & Technol, Multan, Pakistan
[2] Univ Narowal Pakistan, Dept Food Sci & Technol, Narowal, Pakistan
[3] Majmaah Univ, Coll Appl Med Sci, Dept Med Lab Sci, Al Majmaah, Saudi Arabia
[4] Qassim Univ, Coll Med, Dept Pathol, Buraydah, Saudi Arabia
[5] Univ Chenab, Fac Allied Hlth Sci, Gujrat, Pakistan
[6] Jouf Univ, Coll Sci, Dept Chem, Sakaka, Saudi Arabia
[7] Jouf Univ, Coll Pharm, Dept Pharmaceut Chem, Sakaka, Saudi Arabia
[8] AlMaarefa Univ, Coll Pharm, Dept Pharm Practice, Ad Diriyah, Saudi Arabia
[9] Al Azhar Univ, Fac Pharm, Pharmacognosy & Med Plants Dept, Cairo, Egypt
[10] Govt Coll Univ Faisalabad, Dept Food Sci, Faisalabad, Pakistan
[11] MAAR, Agr Extens Directorate, Damascus, Syria
[12] King Edward Med Univ, Dept Biochem, Lahore, Pakistan
关键词
Chrysin; honey; propolis; antioxidant; anticancer; medicinal properties; IN-VITRO; OVARIAN-CANCER; BREAST-CANCER; LUNG-CANCER; BONE CANCER; APOPTOSIS; CELLS; VIVO; EPIDEMIOLOGY; HYPERPLASIA;
D O I
10.1080/10942912.2023.2246678
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Honey, propolis, and passionflower contain a flavone known as chrysin. Researchers are studying chrysin to prove its potential to stop cancer cells growth. Chrysin cancer therapeutic potential is of great interest and numerous studies have been done to illustrate this potential. It is associated protein pathways effectively suppress tumor growth within the body. It is shown to have the ability to kill breast, prostate, lung, liver, and stomach cancerous cells. It can block Phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) and Mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling in different animals against various cancers. Chrysin has the potential to kill breast cancer cells in a laboratory setting by inhibiting their cell division. Chrysin strongly suppresses Matrix metalloproteinase-9 (MMP-9), Urokinase plasminogen activator (uPA) and Vascular endothelial growth factor (VEGF), i.e. factors that can cause cancer. Chrysin has the ability to suppress the androgen receptor (AR), a protein necessary for prostate cancer development and metastasis. It starts the caspase cascade and blocks protein synthesis to kill lung cancer cells. Unnecessary apoptosis can be prevented by stopping certain protein pathways. Chrysin significantly decreased lung cancer metastasis in various animal-modeled studies. Chrysin induces apoptosis and stops colon cancer cells in the G2/M cell cycle phase. Chrysin suppresses colon cancer-promoting cyclin B1 and cyclin-dependent kinase 2. Chrysin suppressed cyclin B1 and CDK2 production in order to stop cancerous growth. Chrysin prevents tumor growth and cancer spread by blocking blood vessel expansion. Chrysin's solubility, accessibility and bioavailability may limit its medical use. Chrysin targets numerous cancer-related communication pathways present in cells. Chrysin may reduce the chances of the onset of cancer, it can also serve as an alternative treatment as a whole to prevent and treat various cancers, but more clinical trials and research studies are needed to fully unlock its potential.
引用
收藏
页码:2294 / 2337
页数:44
相关论文
共 133 条
[1]   Metastatic and triple-negative breast cancer: challenges and treatment options [J].
Al-Mahmood, Sumayah ;
Sapiezynski, Justin ;
Garbuzenko, Olga B. ;
Minko, Tamara .
DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2018, 8 (05) :1483-1507
[2]  
Al-Rimawi F., 2018, AAPS PHARMSCITECH, V19, P919
[3]  
Al-Rimawi F., 2019, PHARMACEUTICS, V11, P503
[4]   Challenges in liver cancer and possible treatment approaches [J].
Anwanwan, David ;
Singh, Santosh Kumar ;
Singh, Shriti ;
Saikam, Varma ;
Singh, Rajesh .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1873 (01)
[5]   Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Argiles, G. ;
Tabernero, J. ;
Labianca, R. ;
Hochhauser, D. ;
Salazar, R. ;
Iveson, T. ;
Laurent-Puig, P. ;
Quirke, P. ;
Yoshino, T. ;
Taieb, J. ;
Martinelli, E. ;
Arnold, D. .
ANNALS OF ONCOLOGY, 2020, 31 (10) :1291-1305
[6]  
Atessahin A., 2019, ANTICANCER RES, V39, P1193
[7]  
Bahadori M, 2016, IRAN J BIOTECHNOL, V14, P117, DOI 10.15171/ijb.1374
[8]   Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [J].
Bewersdorf, Jan Philipp ;
Zeidan, Amer M. .
CANCERS, 2021, 13 (07)
[9]   Thyroid cancer [J].
Cabanillas, Maria E. ;
McFadden, David G. ;
Durante, Cosimo .
LANCET, 2016, 388 (10061) :2783-2795
[10]   Epidemiology and Risk Factors of Melanoma [J].
Carr, Stephanie ;
Smith, Christy ;
Wernberg, Jessica .
SURGICAL CLINICS OF NORTH AMERICA, 2020, 100 (01) :1-+